These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30180467)

  • 1. [Management of toxicities associated with pegaspargase in treatment of patients with lymphoid malignancy: experience from 443 cases in a single center].
    Cong J; Yang L; Ye J; Wei LQ; Li X; Wang JW
    Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):654-660. PubMed ID: 30180467
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia.
    Daley RJ; Rajeeve S; Kabel CC; Pappacena JJ; Stump SE; Lavery JA; Tallman MS; Geyer MB; Park JH
    Leuk Lymphoma; 2021 Jan; 62(1):176-184. PubMed ID: 32985296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.
    Lau KM; Saunders IM; Goodman A
    J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.
    Douer D; Aldoss I; Lunning MA; Burke PW; Ramezani L; Mark L; Vrona J; Park JH; Tallman MS; Avramis VI; Pullarkat V; Mohrbacher AM
    J Clin Oncol; 2014 Mar; 32(9):905-11. PubMed ID: 24516026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication.
    Losasso M; Bostrom B; Messinger Y
    F1000Res; 2019; 8():1007. PubMed ID: 32089823
    [No Abstract]   [Full Text] [Related]  

  • 7. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit.
    Riley DO; Schlefman JM; Vitzthum Von Eckstaedt V HC; Morris AL; Keng MK; El Chaer F
    Curr Hematol Malig Rep; 2021 Jun; 16(3):314-324. PubMed ID: 33978914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegaspargase-induced pancreatitis.
    Alvarez OA; Zimmerman G
    Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical application of asparaginase activity levels following treatment with pegaspargase.
    Bleyer A; Asselin BL; Koontz SE; Hunger SP
    Pediatr Blood Cancer; 2015 Jun; 62(6):1102-5. PubMed ID: 25393506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEGylated
    Verma A; Chen K; Bender C; Gorney N; Leonard W; Barnette P
    Pediatr Hematol Oncol; 2019 Aug; 36(5):277-286. PubMed ID: 31296092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and Efficacy of a 1-Bag Pegaspargase Densensitization Protocol in Pediatric Oncology Patients.
    Cramer J; Graff J; Serebin D
    J Pediatr Hematol Oncol; 2022 Apr; 44(3):e623-e627. PubMed ID: 34133383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study.
    Nadeem K; Colantonio D; Kircanski I; Naqvi A; Hitzler J; Whitlock JA; Dupuis LL
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28044. PubMed ID: 31625674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
    Heo YA; Syed YY; Keam SJ
    Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
    Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
    Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allergic Reactions With Intravenous Compared With Intramuscular Pegaspargase in Children With High-risk Acute Lymphoblastic Leukemia: A Population-based Study From the Maritimes, Canada.
    MacDonald T; Kulkarni K; Bernstein M; Fernandez CV
    J Pediatr Hematol Oncol; 2016 Jul; 38(5):341-4. PubMed ID: 26925715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962).
    Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS
    J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.